---
schema_version: "secwatch.filing_event.v1"
accession: "0001690585-26-000029"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2026-06-12T11:00:32+00:00"
generated_at: "2026-06-12T11:05:31.269348+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Dianthus posts corporate presentation with Phase 3 CAPTIVATE interim data for claseprubart in CIDP

## Summary
- Interim responder analysis data for first 40 patients from Part A of Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy.
- Presentation posted on investor relations website on June 11, 2026.
- No specific numeric results disclosed in the filing text; actual data is in the presentation slides.

## SEC filing metadata
- accession: 0001690585-26-000029
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2026-06-12T11:00:32+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/0001690585-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001690585-26-000029
- JSON: https://secwatch.observer/filing/0001690585-26-000029.json
- Plain text: https://secwatch.observer/filing/0001690585-26-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.